Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Perceptions of innovative orally administered treatment for long-term opioid dependent participants in the SALOME clinical trial

FY 2012-13

Summary
Opioid dependence (i.e., heroin dependence) is a chronic illness that poses great harm to the individual, their family and the wider community. Substitution with oral methadone is the gold standard treatment for opioid dependence, but is not effective for 15 to 25% of chronic opioid dependent individuals. SALOME (Study to Assess Longer-Term Opioid Medication Effectiveness; CIHR-funded) is a randomized, double blind clinical trial testing the effectiveness of hydromorphone (a licensed pain medication; [HDM]) and diacetylmorphine (active ingredient in heroin; [DAM]) as alternative treatments for this population. In Stage I of SALOME, participants are treated with injectable HDM or DAM and in Stage II, half of the participants switch to an oral formulation of HDM or DAM treatment. Despite its effectiveness, treatment with an injectable medication poses some challenges for the health care system (e.g., clinic logistics) and society (e.g., stigma). Thus, the oral treatments in SALOME, if proven effective, have the potential to significantly expand available treatment options for a population that has not benefited from available treatments in Canada. SALOME does not collect data about the delivery of the oral treatment; information that is critical to consider in the planning of future health delivery systems. Therefore, the proposed study is dedicated to analyzing participant's perceptions of oral treatment in SALOME and determining the association between participant's treatment satisfaction with street opioid use at 12 months. Using a mixed qualitative (in-depth interviews) and quantitative (i.e., urinalysis reports, client satisfaction questionnaire) methods approach, data will be triangulated to enrich the theoretical framework being developed. The proposed study will identify the perceptions and outcomes of an innovative treatment alternative for a population that remains outside of the Canadian health care system.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
280115
Name
Marchand Kirsten I
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Canada Graduate Scholarships Master's Awards B
Projecttitle
Perceptions of innovative orally administered treatment for long-term opioid dependent participants in the SALOME clinical trial
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Data Triangulation; Health Services Research; Opioid Dependence; Opioid Substitution Treatment; Qualitative Research Methods; Treatment Perceptions
Abstract
Opioid dependence (i.e., heroin dependence) is a chronic illness that poses great harm to the individual, their family and the wider community. Substitution with oral methadone is the gold standard treatment for opioid dependence, but is not effective for 15 to 25% of chronic opioid dependent individuals. SALOME (Study to Assess Longer-Term Opioid Medication Effectiveness; CIHR-funded) is a randomized, double blind clinical trial testing the effectiveness of hydromorphone (a licensed pain medication; [HDM]) and diacetylmorphine (active ingredient in heroin; [DAM]) as alternative treatments for this population. In Stage I of SALOME, participants are treated with injectable HDM or DAM and in Stage II, half of the participants switch to an oral formulation of HDM or DAM treatment. Despite its effectiveness, treatment with an injectable medication poses some challenges for the health care system (e.g., clinic logistics) and society (e.g., stigma). Thus, the oral treatments in SALOME, if proven effective, have the potential to significantly expand available treatment options for a population that has not benefited from available treatments in Canada. SALOME does not collect data about the delivery of the oral treatment; information that is critical to consider in the planning of future health delivery systems. Therefore, the proposed study is dedicated to analyzing participant's perceptions of oral treatment in SALOME and determining the association between participant's treatment satisfaction with street opioid use at 12 months. Using a mixed qualitative (in-depth interviews) and quantitative (i.e., urinalysis reports, client satisfaction questionnaire) methods approach, data will be triangulated to enrich the theoretical framework being developed. The proposed study will identify the perceptions and outcomes of an innovative treatment alternative for a population that remains outside of the Canadian health care system.
Competitiondate
201302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Marchand, Kirsten I
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~